We have documented that epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK) signaling negatively affects intracellular trafficking and transduction efficiency of recombinant adeno-associated virus 2 (AAV2) vectors. Specifically, inhibition of EGFR-PTK signaling leads to decreased ubiquitination of AAV2 capsid proteins, which in turn, facilitates viral nuclear transport by limiting proteasome-mediated degradation of AAV2 vectors. In the present studies, we observed that AAV capsids can indeed be phosphorylated at tyrosine residues by EGFR-PTK in in vitro phosphorylation assays and that phosphorylated AAV capsids retain their structural integrity. However, although phosphorylated AAV vectors enter cells as efficiently as their unphosphorylated counterparts, their transduction efficiency is significantly reduced. This reduction is not due to impaired viral second-strand DNA synthesis since transduction efficiency of both single-stranded AAV (ssAAV) and self-complementary AAV (scAAV) vectors is decreased by ∼ 68% and ∼ 74%, respectively. We also observed that intracellular trafficking of tyrosine-phosphorylated AAV vectors from cytoplasm to nucleus is significantly decreased, which results from ubiquitination of AAV capsids followed by proteasome-mediated degradation, although downstream consequences of capsid ubiquitination may also be affected by tyrosine-phosphorylation. These studies provide new insights into the role of tyrosinephosphorylation of AAV capsids in various steps in the virus life cycle, which has implications in the optimal use of recombinant AAV vectors in human gene therapy.
Introduction
Recombinant adeno-associated virus 2 (AAV2) vectors have gained attention as an alternative to the more commonly used retrovirus-and adenovirus-based vectors for gene transfer and gene therapy (Berns and Giraud, 1996; Muzyczka, 1992) . A number of Phase I/II clinical trials have been initiated, or are currently underway, that utilize recombinant AAV2 vectors for the potential gene therapy of human diseases such as cystic fibrosis, α-1 anti-trypsin deficiency, Parkinson's disease, Batten's disease, and muscular dystrophy (Flotte et al., 1996 (Flotte et al., , 2004 Kay et al., 2000; Snyder and Francis, 2005) . Recombinant AAV2 vectors have also been reported to transduce a wide variety of cells and tissues in vitro and in vivo (Flotte et al., 1993; Muzyczka, 1992; Snyder et al., 1997; Xiao, Li, and Samulski, 1996) . Several fundamental steps in the life cycle of AAV2 vectors, such as viral binding and entry (Kashiwakura et al., 2005; Qing et al., 1999; Summerford et al., 1999; Summerford and Samulski, 1998) , intracellular trafficking (Douar et al., 2001; Hansen et al., 2000 Sanlioglu et al., 2000; Zhao et al., 2006) , uncoating (Thomas et al., 2004; Zhong et al., 2004c) , second-strand DNA synthesis and transgene expression (Ferrari et al., 1996; Fisher et al., 1996; Qing et al., 1997; Zhong et al., 2004a Zhong et al., , 2004b Zhong et al., , 2004d Zhong et al., , 2008b , and viral genome integration into host cell chromosome (McCarty, Young, and Samulski, 2004; Tan et al., 2001; Zhong et al., 2006) , have been studied extensively.
Previous studies have shown that the ubiquitin-proteasome pathway plays a critical role in intracellular trafficking of AAV2 vectors (Ding et al., 2005 (Ding et al., , 2006 Douar et al., 2001; Duan et al., 2000) . We recently reported that perturbations in EGFR-PTK signaling affects AAV2 transduction efficiency by not only augmenting viral secondstrand DNA synthesis, but also by facilitating intracellular trafficking from the cytoplasm to nucleus (Zhong et al., 2007) . These studies led to the hypothesis that prior to exiting the late endosomes, intact AAV2 particles become phosphorylated at tyrosine residues by EGFR-PTK, which leads to ubiquitination and subsequent degradation of a substantial fraction of the vectors by the cytoplasmic proteasomes, which negatively impacts the efficiency of their transport to the nucleus.
We report here that intact AAV2 capsids can be phosphorylated at tyrosine residues by EGFR-PTK, but not at serine/threonine residues by casein kinase II (CKII), under cell-free conditions in vitro. We also document that tyrosine-phosphorylation of AAV2 capsids negatively affects the viral intracellular trafficking and transgene expression in intact cells in vivo. These studies provide new insights into the role of tyrosine-phosphorylation of AAV2 capsid in various steps in the life cycle of AAV2, which have implications in the optimal use of recombinant AAV2 vectors in human gene therapy.
Results
Intact AAV2 capsids can be phosphorylated at tyrosine residues by EGFR-PTK, but not at serine/threonine residues by CKII, in in vitro phosphorylation assays
One of the predictions from our recently published model was that AAV2 vectors become phosphorylated at tyrosine residues by EGFR-PTK in the late endosome (Zhong et al., 2007) . However, whether intact AAV2 capsid proteins can be phosphorylated at tyrosine and/or serine/threonine residues has not been reported. Using in vitro phosphorylation assays, we first examined whether intact or denatured AAV2 capsid could be phosphorylated by casein kinase II (CKII) or EGFR-PTK. As shown in Fig. 1 , the results clearly indicate that denatured AAV2 capsid proteins (lanes 5 and 8) can be readily phosphorylated in vitro by CKII and EGFR-PTK at serine/threonine and tyrosine residues, respectively. However, intact AAV2 capsids could not be phosphorylated by CKII (lane 4), but phosphorylation at tyrosine residues by EGFR-PTK was readily observed (lane 7). Tyrosine-phosphorylation of AAV2 capsids by EGFR-PTK occurred regardless of the vector production method or the encapsidated transgene. For example, Western blot analyses using anti-phosphotyrosine (anti-p-Tyr) antibody revealed that phospho-tyrosines could not be detected in single-stranded AAV2 (ssAAV2) vectors containing the canine adiponectin gene (K9) produced by the baculovirus-based packaging system, or ssAAV2 vectors containing the red fluorescence protein (RFP), or self-complementary AAV2 (scAAV2) vectors containing the enhanced green fluorescent protein (EGFP) gene generated by the 293 cell-based packaging system ( Fig. 2A, lanes 3 , 5, and 7). However, all vector preparations could be phosphorylated by EGFR-PTK ( Fig. 2A , lanes 4, 6, and 8). We also examined whether in vitro phosphorylation conditions per se lead to vector instability. To this end, following in vitro phosphorylation of AAV2 capsids by EGFR-PTK, intact virions (N100 kDa) were separated from free capsid proteins (30-100 kDa) using centrifugal filter devices [(Ultracel YM-100 (KD) and YM-30 (KD)] and analyzed on Western blots using anti-p-Tyr antibody for detection of phospho-tyrosine containing capsid proteins as well as anti-AAV2 capsid (B1) antibody for detection of total capsid proteins. As shown in Fig. 2B , both the tyrosine-phosphorylated (upper panel) and AAV2 capsid proteins (lower panel) were detected in the N100 kDa fraction (lanes 5 and 6). No signals were detected in the 30-100 kDa fraction (lanes 8 and 9). We conclude, therefore, that tyrosine-phosphorylated AAV2 vectors retain their structural integrity.
Tyrosine-phosphorylated AAV2 vectors are infectious, but their transduction efficiency is significantly reduced
We next evaluated whether tyrosine-phosphorylation affected the biological activity of AAV2 vectors by examining their ability to bind and enter the target cell as well as their ability to express the encapsidated transgene. For the first set of experiments, recombinant AAV2-lacZ vectors were pre-incubated with ATP alone, EGFR-PTK alone, or ATP + EGFR-PTK, and used to infect HeLa cells at 37°C for 2 h under identical conditions. Following exhaustive digestion with trypsin to remove any free virions, low-M r DNA samples were isolated at 2 h post-infection and analyzed on DNA slot-blots using a 32 P-labeled lacZ DNA probe. As can be seen in Fig. 3 , in vitro phosphorylation of AAV2 capsids by EGFR-PTK had no effect on viral binding and entry into HeLa cells.
For the second set of experiments, both ssAAV2 and scAAV2 vectors were used since tyrosine-phosphorylation negatively affects viral second-strand DNA synthesis of ssAAV2 vectors (Mah et al., 1998; Qing et al., 2001 Qing et al., , 1997 Zhong et al., 2004a Zhong et al., , 2004b Zhong et al., , 2004d , and scAAV2 vectors bypass the requirement for viral second-strand DNA synthesis (McCarty et al., 2003; Wang et al., 2003) . HeLa cells were mockinfected or infected with ssAAV2-RFP or scAAV2-EGFP vectors, which were either mock-treated or incubated with ATP alone, EGFR-PTK alone, or ATP + EGFR-PTK, as described above. Transgene expression was detected by fluorescence microscopy 48 h post-infection. As is evident from the results shown in Fig. 4 , in vitro phosphorylation of viral capsids by EGFR-PTK decreased transgene expression by ∼ 68% for ssAAV2 vectors (panels A, B) and by ∼ 74% for scAAV2 vectors (panels C, D). Treatment of viral capsids with CKII, on the other hand, had no effect on either ssAAV2 vectors (panels A, B) or scAAV2 vectors (panels C, D). Thus, we conclude that although tyrosine-phosphorylated AAV2 vectors enter cells as efficiently as their unphosphorylated counterparts, their transduction efficiency is significantly reduced. This reduction is not due to impaired viral second-strand DNA synthesis since transduction efficiency of both ssAAV2 and scAAV2 vectors is affected.
AAV2 capsids are phosphorylated at tyrosine residues following infection, and in vitro phosphorylation of viral capsids at tyrosine residues leads to ubiquitination of intact AAV2 vectors
Since AAV2 vectors could be phosphorylated by EGFR-PTK in vitro, we also wished to evaluate whether intact AAV2 particles also undergo tyrosine-phosphorylation following infection. This was carried out as follows. HeLa cells were either mock-treated or treated with sodium orthovanadate (NaOV), a specific inhibitor of protein phosphatases, and then were either mock-infected or infected with AAV2 vectors for 2 h at 37°C. Whole cell lysates (WCLs) were prepared 4 h post-infection and equivalent amounts of proteins were immunoprecipitated first with anti-AAV2 capsid antibody (A20) followed by Western blot analyses using anti-p-Tyr antibody. These results are shown in Fig. 5A . As can be seen, tyrosine-phosphorylated AAV2 capsid proteins (P-Tyr-AAV2 Cap) were readily detectable in AAV2-infected cells (lanes 1 and 2). No signal was detectable in mockinfected cells (lane 3), and the extent of tyrosine-phosphorylation of AAV2 capsid proteins was increased following treatment with NaOV (lane 2). These results suggest that AAV2 vectors are indeed phosphorylated at tyrosine residues following infection of cells.
We next examined why tyrosine-phosphorylated AAV2 vectors failed to efficiently transduce the target cell. The ubiquitin-proteasome pathway plays an important role in the cell by specifically degrading both endogenous and foreign proteins (Pickart, 2001; Schwartz and Ciechanover, 1999) . Direct evidence for ubiquitination of AAV2 capsid proteins in HeLa cells and in in vitro ubiquitination assays has been reported (Yan et al., 2002) , where only denatured AAV2 capsids, but not intact AAV2, could be ubiquitinated in vitro, which suggested that either a conformational change or a modification, such as phosphorylation of intact AAV2 capsid is required before ubiquitination can ensue. A number of studies have reported that phosphorylation of cellular proteins at tyrosine or serine/threonine residues is required for efficient ubiquitination and degradation of these proteins (Brown et al., 1995; Cenciarelli et al., 1996; Paolini et al., 1999; Penrose et al., 2004) .
Since in our previously published studies (Zhong et al., 2007) , we reported that inhibition of EGFR-PTK signaling decreases ubiquitination of total cellular proteins as well as AAV2 capsid proteins, we examined whether in vitro phosphorylation of viral capsids by EGFR-PTK leads to ubiquitination of AAV2 capsids in intact cells. This was carried out as follows. HeLa cells were either mock-treated or treated with MG132, a specific inhibitor of proteasomes, and then were either mock-infected or infected with AAV2 vectors, with and without tyrosine-phosphorylation, for 2 h at 37°C. Whole cell lysates (WCLs) were prepared 4 h post-infection and equivalent amounts of proteins were immuno-precipitated first with anti-AAV2 capsid antibody (A20) followed by Western blot analyses using anti-Ub monoclonal antibody. These results are shown in Fig. 5B . As can be seen, the ubiquitinated AAV2 capsid proteins (Ub-AAV2 Cap) were undetectable in mock-infected cells (lanes 1 and 2) , the signal of ubiquitinated AAV2 capsid proteins was weaker in untreated cells (lanes 3, 5, 7, and 9), but a significant accumulation of ubiquitinated AAV2 capsid proteins occurred following treatment with MG132 (lanes 4, 6, 8, and 10). Most interestingly, in vitro phosphorylation of viral capsids by EGFR-PTK dramatically increased the extent of accumulation of MG132-induced ubiquitinated AAV2 capsid proteins (lane 6). These results strongly suggest that in vitro phosphorylation of capsids by EGFR-PTK leads to ubiquitination of AAV2 capsids in intact cells. However, since MG132 potentiates capsid ubiquitination as well as increases transduction, it is also possible that capsid ubiquitination serves as a positive sorting signal and not as a negative degradation signal. Thus, tyrosinephosphorylation of AAV2 capsids may limit transduction by affecting other events during infection.
In vitro phosphorylation of viral capsids at tyrosine residues leads to impaired intracellular trafficking to the nucleus
The ubiquitin-proteasome pathway plays a critical role in AAV2 intracellular trafficking, and proteasome inhibitors can promote AAV2 nuclear transport, leading to augmentation of AAV2 transduction (Ding et al., 2005 (Ding et al., , 2006 Douar et al., 2001; Duan et al., 2000) . We have also documented that inhibition of EGFR-PTK signaling facilitates nuclear transport of AAV2 vectors (Zhong et al., 2004c (Zhong et al., , 2007 , which suggested that phosphorylation of AAV2 capsids by EGFR-PTK might also be involved in AAV2 trafficking. To further examine this hypothesis, we examined the cytoplasmic and nuclear distribution of AAV2 genomes following in vitro phosphorylation of AAV2 vectors. HeLa cells were infected with AAV2-lacZ vectors, with or without tyrosine-phosphorylation, as described above. Nuclear and cytoplasmic fractions were obtained 18 h postinfection, and low-M r DNA samples were isolated and analyzed on Southern blots using a 32 P-labeled lacZ DNA probe. These results are shown in Fig. 6 , panel A. A significant fraction of the input ssAAV2 DNA was present in the cytoplasm following infection with AAV2 vectors that were mock-treated or pre-incubated with ATP alone, or with EGFR-TPK alone (lanes 2, 3, and 4), and only a small fraction was detected in the nucleus (lanes 7, 8, and 9). Interestingly, however, in cells infected with AAV2 vectors that were phosphorylated by EGFR-PTK, the input ssAAV2 DNA in the cytoplasmic fraction was increased (lane 5) with a corresponding decrease in the nuclear fraction (lane 10). Densitometric scanning of autoradiographs (Fig. 6, panel B) indicated that ∼35% of the input ssAAV2 DNA was present in the nuclear fraction in cells infected with AAV2 vectors in the absence of tyrosine-phosphorylation, but only ∼ 16% following in vitro phosphorylation at tyrosine residues. These data are consistent with our previous studies (Zhong et al., 2007) , and corroborate that intracellular trafficking of tyrosine-phosphorylated AAV2 vectors from the cytoplasm to the nucleus is significantly decreased, which is due most likely to increased ubiquitination of AAV2 capsids followed by proteasome-mediated degradation. 2) , or infected with K9 vectors, which were mock-incubated (lanes 3 and 4), or incubated with ATP (lanes 7 and 8), EGFR-PTK (lanes 9 and 10) or both (lanes 5 and 6), were immuno-precipitated with anti-AAV2 capsid antibody A20 followed by Western blot analyses with anti-Ub monoclonal antibody P4D1. This result is representative of two independent experiments.
Discussion
Our original observation that specific inhibitors of cellular protein tyrosine kinases in general, and EGFR-PTK in particular, but not inhibitors of cellular serine/threonine kinases, dramatically increase the transduction efficiency of ssAAV vectors (Mah et al., 1998; Qing et al., 1997) , prompted us to pursue a series of studies in which we identified that a cellular chaperone protein, FKBP52, is phosphorylated at tyrosine residues by EGFR-PTK, and that tyrosine-phosphorylated FKBP52 strongly inhibits the viral second-strand DNA synthesis, and consequently the transgene expression (Qing et al., , 2003 Zhong et al., 2004a Zhong et al., , 2004b Zhong et al., , 2004d Zhong et al., , 2008b . More recently, however, we observed that in addition to negatively impacting viral second-strand DNA synthesis and transgene expression in the nucleus, EGFR-PTK-signaling also negatively regulates viral intracellular trafficking in the cytoplasm (Zhong et al., 2007) . Based on these studies, we hypothesized that either prior to or during viral egress from the late endosome, EGFR-PTK catalyzes the phosphorylation of intact AAV2 capsids, which is a putative signal for ubiquitination. Ubiquitinated AAV2 capsids are subsequently targeted for degradation by the cellular proteasome. That intact AAV2 vectors can indeed be phosphorylated at tyrosine residues by EGFR-PTK, both in vitro and in vivo, but not at serine/threonine residues by CKII, as described in the present studies, lends strong support to our hypothesis.
Although the Ub/proteasome pathway has previously been shown to play an essential role in AAV2 nuclear transport (Ding et al., 2005 (Ding et al., , 2006 Douar et al., 2001; Duan et al., 2000) , our data also provide direct evidence that EGFR-PTK-mediated tyrosine-phosphorylation of AAV2 capsids leads to ubiquitination, and subsequent degradation by the proteasome, which impairs viral nuclear transport as well as transduction efficiency of AAV2 vectors. Whether AAV2 vectors can be phosphorylated at serine/threonine residues by other cellular serine/ threonine kinase(s), and what consequences, if any, of serine/ threonine phosphorylation of capsids have on the wild-type (WT) AAV2 biology, remains unclear. What has become clear from our current studies is that phosphorylation of the surface-exposed tyrosine residues on recombinant AAV2 vector capsids is not desirable since site-directed mutagenesis of these tyrosine residues resulted in the generation of AAV2 vectors that are capable of transducing a wide variety of cells and tissues in vitro and in vivo significantly more efficiently than those with the WT capsids (Zhong et al., 2008a) .
Further studies on the precise role of tyrosine-phosphorylation of AAV2 capsids are likely to lead not only to a better understanding of various steps in the virus life cycle, but also to aid in the development of novel recombinant AAV vectors especially in view of the fact that the surface-exposed tyrosine residues are conserved in AAV serotypes 1 through 10, which has implications in the potential use of AAV serotype vectors in human gene therapy.
Materials and methods

Cells, viruses, plasmids, antibodies, and chemicals
The human cervical carcinoma cell line, HeLa, was obtained from the American Type Culture Collection (ATCC, Rockville, MD). The cell line was maintained as monolayer cultures in Iscove's-modified Dulbecco's medium (IMDM) supplemented with 10% newborn calf serum (NCS) and 1% (by volume) of 100× stock solution of antibiotics (10,000 U penicillin + 10,000 μg streptomycin). Highly purified stocks of ssAAV2 vectors containing the β-galactosidase (lacZ) reporter gene, red fluorescence protein (RFP) gene, or scAAV2 vectors containing the enhanced green fluorescence protein (EGFP) gene driven by the chick β-actin (CBA) promoter (ssAAV2-lacZ, ssAAV2-RFP, or scAAV2-EGFP) were generated as described previously (Auricchio et al., 2001) . ssAAV2 vectors containing the canine adiponectin gene (ssAAV2-K9) were generated by a baculovirus-based packaging system as described previously (Urabe et al., 2002) . Physical particle titers of recombinant vector stocks were determined by quantitative DNA slot blot analysis. An AAV2-helper plasmid, pACG-2, containing the AAV2 rep gene with an ACG start codon, was generously provided by Dr. R. Jude Samulski (University of North Carolina at Chapel Hill, Chapel Hill, NC). A self-complementary AAV2 (scAAV2) cloning vector, pdsCBA-EGFP, was a kind gift from Dr. Xiao Xiao (University of North Carolina at Chapel Hill). Horseradish peroxidase (HRP)-conjugated antibody specific for ubiquitin (Ub) (mouse monoclonal immunoglobulin G 1 [IgG 1 ], clone P4D1), antibody specific for phosphorylated tyrosine residues (anti-p-Tyr) (mouse monoclonal IgG 2b , clone PY99), HRP-conjugated goat anti-mouse IgG 2b antibody, HRP-conjugated goat anti-mouse IgG 1 antibody, normal mouse IgG and protein G plus-agarose were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibody specific for intact AAV2 particles (mouse monoclonal IgG 3 , clone A20) and antibody specific for AAV2 capsid proteins (mouse monoclonal IgG 1 , clone B1) were obtained from Research Diagnostics, Inc. (Flanders, NJ). MG132 was purchased from Calbiochem (La Jolla, CA). All other chemicals were purchased from Sigma-Aldrich Co. (St. Louis, MO). 1 and 6) or infected by AAV2-lacZ vectors, which were mock-incubated (lanes 2 and 7) or pre-incubated with ATP (lanes 3 and 8), EGFR-TPK (lanes 4 and 9) or both (lanes 5 and 10). Nuclear and cytoplasmic fractions were prepared 18 h post-infection, low-M r DNA samples were isolated and electrophoresed on 1% agarose gels followed analyzed by Southern blot hybridization using a 
In vitro phosphorylation assays
In vitro phosphorylation by CKII (Calbiochem, La Jolla, CA) was carried out as previously described Zhong et al., 2004d) . Briefly, the complete reaction mixture contained identical amount of intact or denatured AAV2 vectors (∼3-4.8 × 10 10 viral particles), 20 mM Tris-HCl, 50 mM KCl, 10 mM MgCl 2 , 50 mM Na 3 VO4, 10 μCi (0.37 mBq) γ-32 P-ATP and 500 U (500,000 U/ml) purified CKII. In vitro phosphorylation by EGFR-PTK was carried out as described previously Weber et al., 1984; Zhong et al., 2004d) , with the following modifications. The complete reaction mixture contained identical amounts of intact or denatured AAV2 vectors (∼3-4.8 × 10 10 viral particles), 20 mM HEPES, 4 mM MgCl 2 , 10 mM MnCl 2 , 10 μCi (0.37 mBq) γ-32 P-ATP and 10 U (15,000 U/mg) purified EGFR-PTK (Sigma-Aldrich Co., St. Louis, MO) with the indicated appropriate controls. The reaction mixtures were incubated at 30°C for 1 h. The phosphorylated AAV2 capsid proteins were separated from free γ-32 P-ATP on 10% SDS-polyacrylamide gels followed by autoradiography with Kodak 7 X-Omat film at −70°C. In some experiments, in vitro phosphorylation assays by EGFR-PTK were also carried out by adding 200 μM ATP instead of γ-32 P-ATP.
The phosphorylated AAV2 capsid proteins were identified by Western blotting with anti-p-Tyr antibody as described below.
Separation of intact AAV2 virions and AAV2 capsid proteins using ultrafiltration assay
After in vitro phosphorylation assays, the reaction samples plus 450 μl of phosphate buffered saline (PBS, pH7.4) were added into the upper part of the YM-100 Microcon ® centrifugal filter device (cutoff value: 100 kDa) (Millipore Corporation, Bedford, MA) and centrifuged at 14,000 ×g for 24 min at 4°C. Approximately 10-20 μl of ultrafiltrates was collected. The flow through samples were added into the upper part of the YM-30 Microcon ® centrifugal filter device (cutoff value: 30 kDa) (Millipore Corporation, Bedford, MA) and centrifuged at 14,000 ×g for 24 min at 4°C. Approximately 10-20 μl of ultrafiltrates was collected. The ultrafiltrate samples were analyzed by Western blotting using anti-p-Tyr and anti-AAV2 cap (B1) antibodies as described below.
Preparation of whole cell lysates (WCLs) and co-immunoprecipitations
WCLs were prepared as described previously Zhong et al., 2004d; Zhong and Su, 2002) , with the following modifications. Briefly, 2 × 10 6 HeLa cells were either mock-treated, treated with, 1 mM NaOV for 2 h and then were infected with AAV2-adiponectin vectors at 10 4 particles/cell for 2 h at 37°C. In some experiments cells were either mock-treated or treated with 4 μM MG132 for 4 h and then were infected with AAV2-adiponectin vectors at 10 4 particles/cell for 2 h at 37°C, which were mockincubated or pre-incubated with ATP, EGFR-TPK, or both. For immunoprecipitations, cells were treated with 0.01% trypsin and washed extensively with PBS to remove any adsorbed and unadsorbed virus particles after treatment or at 4 h post-infection and then resuspended in 1 ml hypotonic buffer (20 mM HEPES pH 7.5, 5 mM KCl, 0.5 mM MgCl 2 ) containing 1 mM DTT, 10 mM NaF, 2 mM Na 3 VO 4 , 0.5 mM PMSF, 10 μg/ml aprotinin, 10 μg/ml leupeptin and 10 μg/ml. WCLs were prepared by homogenization in a tightfitting Duall tissue grinder until about 95% cell lysis was achieved as monitored by trypan blue dye exclusion assay. WCLs were cleared of non-specific binding by incubation with 0.25 mg of normal mouse IgG together with 20 μl of protein G plus-agarose beads for 60 min at 4°C in an orbital shaker. After preclearing, 2 μg of capsid antibody against intact AAV2 particles (A20) (mouse IgG 3 ) or 2 μg of normal mouse IgG (as a negative control) was added and incubated at 4°C for 1 h, followed by precipitation with protein G-agarose beads at 4°C for 12 h in a shaker. Pellets were collected by centrifugation at 2500 rpm for 5 min at 4°C and washed four times with PBS. After the final wash, supernatants were aspirated and discarded, and pellets were resuspended in equal volume of 2× SDS sample buffer. Twenty μl of resuspended pellet solutions were used for Western blotting with HRP-conjugated anti-Ub antibody as described below.
Western blot analyses
Western blotting was performed as described previously Zhong et al., 2004d; Zhong and Su, 2002) . For in vitro phosphorylation assays, the reaction mixtures were separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Immobilon-P membranes (Millipore, Bedford, MA). Membranes were blocked at 4°C for 12 h with 5% nonfat milk in 1× Tris-buffered saline (TBS, 20 mM Tris-HCl, pH 7.5, 150 mM NaCl). Membranes were treated with monoclonal anti-p-Tyr antibody (1:300 dilution) or monoclonal anti-AAV2 capsid proteins antibody followed by horseradish peroxidase-conjugated anti-mouse IgG 2b or anti-mouse IgG 1 (1:10,000 dilution). For immunoprecipitations, resuspended pellet solutions were boiled for 2-3 min and 20 μl of samples were used for SDS-PAGE. After blocking at 4°C for 12 h with 5% nonfat milk in 1× Tris-buffered saline, membranes were treated with monoclonal HRP-conjugated anti-Ub antibody (1:2000 dilution). Immuno-reactive bands were visualized using chemiluminescence (ECL-plus, Amersham Pharmacia Biotech, Piscataway, NJ).
Isolation of nuclear and cytoplasmic fractions from HeLa cells
Nuclear and cytoplasmic fractions from HeLa cells were isolated as described previously (Zhong et al., 2004c (Zhong et al., , 2007 . Briefly, mockinfected or recombinant ssAAV2-lacZ vector-infected cells were washed twice with PBS at 18 h post-infection, treated with 0.01% trypsin and washed extensively with PBS to remove any adsorbed and unadsorbed virus particles. Cell pellets were gently resuspended in 200 μl hypotonic buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT, 0.5 mM PMSF) and incubated on ice for 5 min, after which 10 μl 10% NP-40 was added, and observed under a light microscope. Samples were mixed gently and centrifuged for 5 min at 500 rpm at 4°C. Supernatants (cytoplasmic fraction) were decanted and stored on ice. Pellets (nuclear fractions) were washed twice with 1 ml hypotonic buffer and stored on ice. The purity of each fraction was determined to be N95%, as measured by the absence of acid phosphatase activity (nuclear fractions) and absence of histone H3 (cytoplasmic fractions) as described previously (Hansen et al., 2000; Zhong et al., 2004c) .
Southern blot analysis for AAV2 trafficking
Low-M r DNA samples from nuclear and cytoplasmic fractions were isolated and electrophoresed on 1% agarose gels or 1% alkaline-agarose gels followed by Southern blot hybridization using a 32 P-labeled lacZ-specific DNA probe as described previously (Hansen et al., 2000; Zhong et al., 2004c) . Densitometric scanning of autoradiographs for the quantitation was evaluated with ImageJ analysis software (NIH, Bethesda, MD).
Recombinant AAV2 vector transduction assays
Approximately 1 × 10 5 HeLa cells were plated in each well in 12-well plates and incubated at 37°C for 12 h. Cells were washed once with IMDM and then infected at 37°C for 2 h with recombinant AAV2 vectors as described previously Zhong et al., 2004a Zhong et al., , 2004d . Cells were incubated in complete IMDM containing 10% NCS and 1% antibiotics for 48 h. The transduction efficiency was measured by EGFP imaging using a Leica DM IRB/E fluorescence microscope (Leica Microsystems Wetzlar GmbH, Wetzlar, Germany). Images from three to five visual fields of mock-infected and vector-infected HeLa cells at 48 h post-infection were analyzed quantitatively by ImageJ analysis software (NIH, Bethesda, MD, USA). Transgene expression was assessed as total area of green fluorescence (pixel 2 ) per visual field (mean ± SD). Analysis of variance (ANOVA) was used to compare between test results and the control and they were determined to be statistically significant.
